Invesco Ltd. Sells 28,002 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)

Invesco Ltd. lowered its holdings in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 54.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,288 shares of the biotechnology company's stock after selling 28,002 shares during the period. Invesco Ltd. owned about 0.08% of AnaptysBio worth $308,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of ANAB. KLP Kapitalforvaltning AS bought a new stake in AnaptysBio in the 4th quarter worth approximately $40,000. AlphaQuest LLC grew its holdings in shares of AnaptysBio by 1,891.5% in the fourth quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company's stock worth $59,000 after purchasing an additional 4,237 shares during the last quarter. Russell Investments Group Ltd. increased its stake in shares of AnaptysBio by 1,585.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,698 shares of the biotechnology company's stock worth $75,000 after buying an additional 5,360 shares during the period. China Universal Asset Management Co. Ltd. increased its position in shares of AnaptysBio by 11.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company's stock valued at $85,000 after acquiring an additional 644 shares during the period. Finally, Aristides Capital LLC bought a new position in AnaptysBio during the 4th quarter valued at approximately $168,000.

Analyst Ratings Changes

Several research firms recently weighed in on ANAB. Johnson Rice reiterated a "buy" rating on shares of AnaptysBio in a report on Wednesday, March 26th. Wedbush restated an "outperform" rating and issued a $40.00 price objective on shares of AnaptysBio in a report on Thursday, May 1st. HC Wainwright reissued a "neutral" rating and issued a $22.00 target price on shares of AnaptysBio in a research report on Tuesday, March 4th. Wells Fargo & Company increased their price objective on AnaptysBio from $40.00 to $51.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. Finally, Guggenheim increased their price target on shares of AnaptysBio from $52.00 to $54.00 and gave the stock a "buy" rating in a research note on Tuesday. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $35.88.

AnaptysBio Price Performance

Shares of ANAB stock traded down $0.09 during trading hours on Friday, hitting $19.49. The stock had a trading volume of 132,385 shares, compared to its average volume of 594,334. The stock has a market capitalization of $576.40 million, a price-to-earnings ratio of -3.21 and a beta of -0.20. AnaptysBio, Inc. has a one year low of $12.21 and a one year high of $41.31. The stock's 50-day moving average price is $18.55 and its two-hundred day moving average price is $18.81.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last posted its earnings results on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share for the quarter, beating analysts' consensus estimates of ($1.30) by $0.02. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The firm had revenue of $27.77 million during the quarter, compared to analyst estimates of $15.27 million. As a group, equities research analysts predict that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio declared that its board has authorized a stock buyback plan on Monday, March 24th that authorizes the company to buyback $75.00 million in outstanding shares. This buyback authorization authorizes the biotechnology company to reacquire up to 13.1% of its shares through open market purchases. Shares buyback plans are often an indication that the company's board believes its stock is undervalued.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.